Quality Of Life (Qol) And Clinical Outcomes In Patients With Relapsed/Refractory Multiple Myeloma (Rrmm) Receiving Ixazomib-Lenalidomide-Dexamethasone (Ird) In A Real-World Setting

Tatyana Ionova, Elena Ado,Lyudmila Anchukova, Elena Babich,Dolgorzhap Dasheeva, Marina Demchenkova,Sergei Dubov, Tatiana Esenina, Lyudmila Ivanova,Kamil Kaplanov, Anna Kopylova,Yulia Kochkareva, Tatiana Kravchuk, Alexander Levanov, Olga Li,Tatiana Mitina,Tatiana Nikitina,Natalia Porfirieva, Elena Rimashevskaya, Oleg Rukavitsyn,Natalia Saraeva, Marina Savinova,Tatiana Shelekhova, Polina Simashova,Mariya Shirokova,Olga Vinogradova, Svetlana Volkova,Anna Zinkovskaya

BLOOD（2020）

引用 0|浏览15

暂无评分

摘要

The goal of treatment of relapsed/refractory multiple myeloma (RRMM) is to control the disease, prolong survival, reduce disease-related symptoms, and improve quality of life (QoL). Comprehensive evaluation of new treatment regimens in RRMM pts is worthwhile. We aimed to evaluate QoL, treatment satisfaction, response to treatment and safety during Ixazomib-Lenalidomide-Dexamethasone (IRd) treatment as ≥ 2nd line in RRMM pts in a real world setting.

查看译文

关键词

relapsed/refractory multiple myeloma,multiple myeloma,clinical outcomes,ixazomib-lenalidomide-dexamethasone,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要